APA (7th ed.) Citation

Ramani, V. K., Gayen, S., & Naik, R. An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers. Wiley.

Chicago Style (17th ed.) Citation

Ramani, Vinod K., Srimonta Gayen, and Radheshyam Naik. An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers. Wiley.

MLA (9th ed.) Citation

Ramani, Vinod K., et al. An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers. Wiley.